Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucia Taramasso

Showing results (61-70 of 137) with videos related to

Pageof 14
Sort By:
The New Microbiologica|January 22, 2024
Optimizing the antiretroviral treatment focusing on long-term effectiveness and a person-centered approach. Consensus Guidance Using a Delphi ProcessFranco Maggiolo, Sergio Lo Caputo, Stefano Bonora, et al.
The Journal of Antimicrobial Chemotherapy|September 11, 2019
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohortLucia Taramasso, Patrizia Lorenzini, Antonio Di Biagio, et al.
International Journal of Antimicrobial Agents|August 28, 2016
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglyceridesAntonio Di Biagio, Niccolò Riccardi, Lucia Taramasso, et al.
Mycoses|February 9, 2022
Aspergillus-PCR in bronchoalveolar lavage - diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patientsMalgorzata Mikulska, Elisa Furfaro, Silvia Dettori, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2023
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA studyAntonella D'arminio Monforte, Alessandro Tavelli, Matteo Sala, et al.
Open Forum Infectious Diseases|December 20, 2017
Weight Gain: A Possible Side Effect of All AntiretroviralsLucia Taramasso, Elena Ricci, Barbara Menzaghi, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2025
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIVLucia Taramasso, Stefano Bonora, Antonella Cingolani, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 26, 2026
Pre-ART platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio and the risk of non-AIDS-events, AIDS-events and mortality in people with HIVPaola Saltini, Alessandro Cozzi-Lepri, Giorgio Bozzi, et al.
Journal of Hypertension|December 23, 2016
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension StudyGiuseppe Vittorio De Socio, Elena Ricci, Paolo Maggi, et al.
Infection and Drug Resistance|June 20, 2019
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA projectPaola Bagella, Nicola Squillace, Elena Ricci, et al.
Pageof 14

Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
The New Microbiologica|January 22, 2024
Optimizing the antiretroviral treatment focusing on long-term effectiveness and a person-centered approach. Consensus Guidance Using a Delphi ProcessFranco Maggiolo, Sergio Lo Caputo, Stefano Bonora, et al.
The Journal of Antimicrobial Chemotherapy|September 11, 2019
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohortLucia Taramasso, Patrizia Lorenzini, Antonio Di Biagio, et al.
International Journal of Antimicrobial Agents|August 28, 2016
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglyceridesAntonio Di Biagio, Niccolò Riccardi, Lucia Taramasso, et al.
Mycoses|February 9, 2022
Aspergillus-PCR in bronchoalveolar lavage - diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patientsMalgorzata Mikulska, Elisa Furfaro, Silvia Dettori, et al.
The Journal of Antimicrobial Chemotherapy|February 13, 2023
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA studyAntonella D'arminio Monforte, Alessandro Tavelli, Matteo Sala, et al.
Open Forum Infectious Diseases|December 20, 2017
Weight Gain: A Possible Side Effect of All AntiretroviralsLucia Taramasso, Elena Ricci, Barbara Menzaghi, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2025
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIVLucia Taramasso, Stefano Bonora, Antonella Cingolani, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 26, 2026
Pre-ART platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio and the risk of non-AIDS-events, AIDS-events and mortality in people with HIVPaola Saltini, Alessandro Cozzi-Lepri, Giorgio Bozzi, et al.
Journal of Hypertension|December 23, 2016
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension StudyGiuseppe Vittorio De Socio, Elena Ricci, Paolo Maggi, et al.
Infection and Drug Resistance|June 20, 2019
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA projectPaola Bagella, Nicola Squillace, Elena Ricci, et al.
Pageof 14